Half year report on Adocia's liquidity agreement with DSF Markets

Regulatory News:

Under the liquidity agreement entrusted by Adocia (Paris:ADOC) to DFS Markets (formerly named BIL Finance), the following assets appeared on the liquidity account as at December 31, 2013:

• 40,326 shares of Adocia and
• 215,305.78 euros in cash.

As the reminder, the following assets appeared on the liquidity account at the latest report dated on June 30, 2013:

• 27,311 shares of Adocia and
• 348,835.66 euros in cash.

As a reminder, the liquidity agreement was concluded on March 14, 2012 with an initial contribution amounting to 500,000 euros.

About Adocia:

To be a global leader for the formulation of therapeutic proteins

Adocia is a biotech company specialized in the development of best-in-class drugs from the innovative formulation of certain already-approved therapeutic proteins.

Adocia is specialized in insulin therapy and the treatment of the diabetic foot, one of the main complications of diabetes.

Adocia successfully completed two phases I and II studies on the formulation of a fast-acting human insulin and obtained promising phase I/II results on a diabetic foot ulcer-healing product. Furthermore, Adocia has launched mid-November a Phase I clinical trial on a unique combination of fast-acting insulin and slow-acting insulin, for an optimal insulin therapy with one single product.

Based on its experience and recognized know-how, Adocia has extended its activities to the formulation of monoclonal antibodies, which are gold standard molecules for the treatment of numerous chronic pathologies (oncology, inflammation, etc.). In this field, Adocia is engaged in collaborative programs with two major pharmaceutical companies.

Fight cancer by enhancing oncology treatments targeting

Late in 2013, Adocia acquired an exclusive license on a nanotechnology which improves oncology treatments efficacy by targeting their action to solid tumors. This nanotechnology, called DriveIn®, is remarkably efficient in carrying active molecules and delivering them within solid tumors. This new platform in nanotechnology is an exceptional opportunity to enter the oncology market by improving the efficacy of already approved treatments.

Adocia develops proprietary products based on doxorubicin and docetaxel, two of the most used anti-tumoral treatments, which could greatly benefit from an enhanced intra-cellular delivery. Adocia will also propose the DriveIn technology to pharmaceutical companies to optimize the efficacy of their own proprietary molecules.

"Innovative medicine for everyone, everywhere"

Through its BioChaperone® state-of-the-art technological platform, Adocia intends to enhance the effectiveness and safety of therapeutic proteins and their ease of use for patients, with the aim of making these medicines accessible to the broadest public.

Adocia's therapeutic innovations aim at bringing solutions to a profoundly changing global pharmaceutical and economic context, characterized in particular by the increased prevalence and impact of the targeted pathologies, population growth and ageing, the need to control public health expenditures and increasing demand from emerging countries.

Adocia is listed on the regulated market of Euronext in Paris (ISIN: FR0011184241, mnemo / Reuters / Bloomberg: ADOC, ADOC.PA, ADOC.FP) and its share included in the Next Biotech index.

For more information: www.adocia.com

Adocia
Gérard Soula, [phone]
Chairman and CEO of Adocia
[e-mail]
or
Press Relations
Andrew Lloyd & Associates
Juliette dos Santos /Sandra Régnavaque, [phone]
[e-mail] ? [e-mail]
or
Financial communication & Investor Relations
NewCap
Pierre Laurent / Julien Perez, [phone]
[e-mail]